In a landmark decision poised to reshape access to one of the world’s most sought-after medications, Health Canada has granted…
Read More
Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio
Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
In a landmark decision poised to reshape access to one of the world’s most in-demand medications, Health Canada has granted…
Read More
Genprex Secures Canadian Patent for Novel Cancer Therapy Combination
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the…
Read More
Biopharma M&A Surges as Billion-Dollar Deals Fuel Pipeline Replenishment Amidst Patent Cliff Pressures
The biopharmaceutical industry is experiencing a significant resurgence in merger and acquisition (M&A) activity, driven by a wave of high-value…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The pharmaceutical landscape for diabetes and weight management medications has undergone a significant shift with Health Canada’s authorization of Dr.…
Read More
Canada Makes History as First G7 Nation to Approve Generic Semaglutide, Sparking Global Debate on Patent Enforcement and Drug Access
In a landmark decision poised to reshape the landscape of diabetes and obesity management, Health Canada has granted authorization to…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide as Novo Nordisk Patent Lapses
In a landmark decision poised to reshape the pharmaceutical landscape and significantly impact patient access and healthcare costs, Health Canada…
Read More
The Eliquis Patent Cliff: A $14.2 Billion Revenue Erosion Set to Reshape Pharmaceutical Giants
The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The Canadian healthcare landscape is poised for a significant transformation with Health Canada’s authorization of Dr. Reddy’s Laboratories’ generic semaglutide…
Read MoreYOU MAY HAVE MISSED
